# STANDARD MEDICARE PART B MANAGEMENT

## Strontium Chloride Sr-89 (METASTRON)

#### **POLICY**

## I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

## FDA-Approved Indication

Indicated for the relief of bone pain in patients with painful skeletal metastases.

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

#### II. DOCUMENTATION

The following documentation must be available, upon request, for all submissions: Documentation of the presence of bone metastases

## III. CRITERIA FOR INITIAL APPROVAL

#### **Malignant Bone Pain**

Authorization of 12 months may be granted for the relief of bone pain when all of the following criteria are met:

- 1. The member has a malignant/cancer diagnosis
- 2. The member has bone metastases

#### IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization of 12 months may be granted when all of the following criteria are met:

- 1. The member is currently receiving therapy with the requested medication
- 2. The requested medication is being used to treat an indication enumerated in Section III
- 3. There is no evidence of unacceptable toxicity while on the current regimen

Strontium Chloride Sr 89-Metastron 5750-A MedB CMS P2023.docx

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



## V. SUMMARY OF EVIDENCE

The contents of this policy were created after examining the following resources:

- 1. The prescribing information for strontium chloride Sr-89.
- 2. The available compendium
  - a. National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
  - b. Micromedex DrugDex
  - c. American Hospital Formulary Service- Drug Information (AHFS-DI)
  - d. Lexi-Drugs
  - e. Clinical Pharmacology


After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for strontium chloride Sr-89 are covered.

#### VI. EXPLANATION OF RATIONALE

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

## VII. REFERENCES

1. Strontium Chloride Sr-89 [package insert]. New York, NY: Q BioMed, Inc.; January 2020.



© 2023 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written